A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions

Summary

This is a Phase 1/1b, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antineoplastic activity of APS03118 administered orally in participants with RET-altered solid tumors.

Timeline

Start

2023-02-06

Primary completion

2026-10

Completion

2026-10

Drugs

Indications